Stryker has signed a definitive agreement to acquire ZuriMED, a privately held developer of the FiberLocker System used in rotator cuff repair. Lenz & Staehelin advised Stryker on the transaction, which remains subject to customary closing conditions.
Schellenberg Wittmer acted as Swiss counsel to Marubeni Corporation on its acquisition of Tolus Group, a Swiss machine tool company, while Herbert Smith Freehills Kramer served as international lead counsel on the transaction.
Corporate
Deal & transactions
Bär & Karrer advises on Edisun’s acquisition of Smartenergy’s operations
Bär & Karrer is providing legal counsel on capital markets and competition law aspects of Edisun Power Europe's acquisition of Smartenergy Group's business operations, a transaction valued at approximately CHF 440 million that will see
Walder Wyss advised UBS Switzerland as mandated lead arranger on the refinancing and increase of secured syndicated credit facilities worth CHF 50 million and USD 31.5 million for medtech company SpineArt.
Boehringer Ingelheim, a globally active human and animal pharmaceutical company with headquarters in Ingelheim (Germany), completed the acquisition of Evax, a Swiss biotech company focused on equine health. In connection with the deal, Schellenberg Wittmer
Walder Wyss advised Vaderis Therapeutics, a Swiss clinical-stage biopharmaceutical company developing targeted therapies for rare vascular diseases, throughout completion of a USD 152 million Series B financing, leading to the initiation of Heroic, the company’s
Kellerhals Carrard and Wilson Sonsini Goodrich & Rosati advised Gravis Robotics, a company specialised on physical AI for heavy machinery with headquarters in Zurich (Switzerland), Austin (USA), and Oxford (UK) on its USD 200 million series
Swiss firms Bär & Karrer and Vischer advised the gipser.ch Group as the company has entered into a strategic partnership with Rossi Aregger AG. Based in Baar (ZG), Rossi Aregger provides plastering and
Niederer Kraft Frey (NKF) advised the shareholder of Wonderhotels SA on the sale of all shares in Wonderhotels SA, including the Hotel De La Paix in Lugano, to ESMO, the European Society for Medical Oncology,
Vischer advised Royalty Pharma Investments on its acquisition of a portion of Neurimmune’s royalty interest in cliramitug for up to USD 425 million, including USD 125 million upfront. Cliramitug is an investigational human monoclonal antibody discovered
